INT121475

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2004
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 2.43
Pain Relevance 0.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Twist1) nucleus (Twist1) DNA binding (Twist1)
transcription factor binding (Twist1)
Anatomy Link Frequency
plasma 2
smooth muscle 2
extracellular matrix 2
Twist1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 77 98.04 Very High Very High Very High
antagonist 3 27.28 Quite Low
anesthesia 2 25.00 Low Low
metalloproteinase 10 10.56 Low Low
Inflammatory mediators 8 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
adenocard 4 5.00 Very Low Very Low Very Low
cINOD 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Inflammatory response 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Disease 62 99.84 Very High Very High Very High
INFLAMMATION 89 98.04 Very High Very High Very High
Adhesions 19 97.88 Very High Very High Very High
Pulmonary Hypertension 35 88.80 High High
Hypertrophy 4 87.44 High High
Vomiting 10 77.76 Quite High
Congenital Anomalies 5 76.40 Quite High
Increased Venous Pressure Under Development 15 63.44 Quite High
Body Weight 5 57.76 Quite High
Disease 15 38.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To study the effect of phosphodiesterase (PDE) 3 inhibition on plasma insulin and glucose levels, the selective PDE 3 inhibitor milrinone (0.25, 1.0, and 2.5 mg/kg) was given orally to anesthetized CL57Bl/6J mice 10 min before a gastric glucose gavage (150 mg/mouse).
Regulation (effect) of Negative_regulation (inhibition) of PDE in plasma
1) Confidence 0.14 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15364011 Disease Relevance 0 Pain Relevance 0
Clinical effects of PDE inhibitors in COPD
Regulation (effects) of Negative_regulation (inhibitors) of PDE associated with pulmonary disease
2) Confidence 0.03 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.66 Pain Relevance 0.11
As a result of greater knowledge about isoforms of PDE and their role in regulating inflammatory cells and airway and vascular smooth muscle there has been considerable interest in the clinical effects of PDE inhibitors in patients with COPD.
Regulation (effects) of Negative_regulation (inhibitors) of PDE in smooth muscle associated with pulmonary disease and inflammation
3) Confidence 0.02 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.76 Pain Relevance 0.13
In this model we examined (i) the acute pulmonary vasodilatory efficacy of inhaled tolafentrine (ii) the anti-remodeling effect of long-term inhalation of tolafentrine (iii) the inhibitory effect of tolafentrine on pulmonary artery SMC cell migration, and (iv) the effect of the PDE inhibitor on the expression profile of 96 genes encoding cell adhesion and extracellular matrix regulation.
Regulation (effect) of Negative_regulation (inhibitor) of PDE in extracellular matrix associated with adhesions
4) Confidence 0.01 Published 2005 Journal Respir Res Section Body Doc Link PMC1291406 Disease Relevance 1.01 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox